Stocks / Sun Pharmaceutical Industries (SUNPHARMA)

SUNPHARMA Share Price, Analysis & News

Sun Pharmaceutical Industries (SUNPHARMA) — Updated on 2026-06-22

Sun Pharmaceutical Industries Limited operates within the biotechnology & drugs sector, focusing on specialty generic pharmaceuticals. The company's business model encompasses specialty, generics, and consumer healthcare products, with a global specialty portfolio that includes dermatology treatments. Investors closely monitor Sun Pharmaceutical Industries share price to understand its performance and potential. Analysis of the company's fundamentals, earnings, and broader sector trends in biotechnology and pharmaceuticals provides insights into its market position and future prospects. The company's operations are centered around developing and marketing a diverse range of pharmaceutical offerings.
Overview Daily Weekly

Key Takeaway

Sun Pharma shows strong bullish momentum near 52-week highs, underpinned by robust year-on-year growth despite a recent sequential profit dip.

Daily

2026-06-22
  • The stock is exhibiting strong bullish momentum, with positive short-term returns of 1.32% in one day and 3.13% over five days, supported by a bullish trend alignment score of 3 and a strong RSI of 64.55.
  • Technically, the stock is trading above its 50-day and 200-day moving averages, by 3.54% and 6.63% respectively, and is positioned near its 52-week high, down by only 2.26%, indicating sustained upward price action.
  • While the stock shows robust year-on-year growth in revenue (12.756%), net profit (25.812%), and EPS (26.228%), the latest quarter experienced a sequential decline in these metrics (-5.857% revenue, -19.846% profit, -19.444% EPS), suggesting a potential short-term slowdown.
  • Analysts maintain a largely positive outlook, with 87.88% of ratings being 'Buy' or 'Strong Buy', and there's been a recent increase in 'Strong Buy' ratings from 9 to 10, indicating growing analyst confidence.
  • The company has announced the transfer of equity shares and unclaimed dividends to the Investor Education and Protection Fund (IEPF) Account, a regulatory filing that occurred on June 16, 2026.
  • A news highlight indicates that the stock is expected to remain in focus on Monday, June 22, as mentioned in a Businessline article, suggesting potential market attention.
Open daily analysis

Weekly

Latest weekly signal
  • The stock price rose by 1.84% this week, continuing a positive trend for the second consecutive week, supported by strong technical indicators including a bullish MACD crossover and an RSI above 50.
  • Sun Pharma's technicals show a strengthening upward trend with the price trading above key moving averages (20-week and 50-week MAs) and improving momentum indicators.
  • The company announced its 34th AGM on July 31, 2026, with a record date of July 7, 2026, for a final dividend of ₹5 per share for FY2025-26.
  • A significant event this week was CRISIL placing Sun Pharma's long-term rating on 'Watch Developing' following the agreement to acquire Organon for $11.75 billion.
  • News highlighted Sun Pharma among Nifty stocks showing a bullish RSI upswing, indicating improving momentum, while the broader market reacted positively to geopolitical developments.
Open weekly analysis

Quarterly

Latest quarterly update
Detailed analysis available on the full page.

Price & Technical Structure

  • The stock has shown positive short-term returns, with a 1-day return of 1.32% and a 5-day return of 3.13%.
  • The trend is bullish, indicated by a positive distance from both the 50-day and 200-day moving averages (3.54% and 6.63% respectively) and a bullish trend alignment score of 3.
  • Momentum is strong, with an RSI of 64.55 and a bullish MACD signal.
  • Volatility is elevated, with the price trading above the upper Bollinger Band (105.13% of the upper band) and a band width of 5.43%.
  • The stock is positioned near its 52-week high, down by only 2.26%, and has a current drawdown of -2.26%.
The market behaviour indicates a strong bullish trend with positive short-term returns and robust momentum, as evidenced by RSI and MACD. The price is trading above key EMAs and the upper Bollinger Band, suggesting upward momentum but also potential overbought conditions. The stock is also trading close to its 52-week high, with a minimal current drawdown, reinforcing the bullish sentiment. Volume analysis, while not showing accumulation, does not contradict the prevailing bullish trend.

Weekly Momentum

  • The stock price rose by 1.84% this week, continuing a positive trend for the second consecutive week, supported by strong technical indicators including a bullish MACD crossover and an RSI above 50.
  • Sun Pharma's technicals show a strengthening upward trend with the price trading above key moving averages (20-week and 50-week MAs) and improving momentum indicators.
  • The company announced its 34th AGM on July 31, 2026, with a record date of July 7, 2026, for a final dividend of ₹5 per share for FY2025-26.
  • A significant event this week was CRISIL placing Sun Pharma's long-term rating on 'Watch Developing' following the agreement to acquire Organon for $11.75 billion.
  • News highlighted Sun Pharma among Nifty stocks showing a bullish RSI upswing, indicating improving momentum, while the broader market reacted positively to geopolitical developments.
Sun Pharma's stock is experiencing a positive technical momentum, evidenced by its price trading above key moving averages and improving momentum indicators like RSI and MACD. This is occurring alongside significant corporate activity, including a major acquisition and a rating watch from CRISIL due to this acquisition. The company also announced its AGM and dividend record date. Market sentiment appears cautiously optimistic, with the stock benefiting from positive technicals and broader market trends, despite some sectoral pressure.